<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160042</url>
  </required_header>
  <id_info>
    <org_study_id>8313</org_study_id>
    <nct_id>NCT01160042</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fasting Condition</brief_title>
  <official_title>A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Metformin Hydrochloride 1000 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics, India) to be Compared With Glucophage® (Metformin Hydrochloride) 1000 mg Tablets (Bristol-Myers Squibb, USA) in 52 + (2 Standby) Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
      To compare the single dose bioavailability of Metformin Hydrochloride 1000 mg tablets (Dr.&#xD;
      Reddy's Laboratories Ltd., Generics, India) with Glucophage (Metformin Hydrochloride) 1000 mg&#xD;
      tablets (Bristol-Myers Squibb, USA) in 52 + (2 standby) healthy, adult, human subjects under&#xD;
      fasting conditions.&#xD;
&#xD;
      To monitor adverse events and to ensure the safety of subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-period, two-sequence, single&#xD;
      dose,crossover bioequivalence study with at least 07 days of washout period between each drug&#xD;
      administration under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax, AUC, Tmax,t1/2 parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucophage 1000 mg tablets of Bristol-Myers Squibb</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin Tablets 1000 mg</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage Tablets 1000 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage</intervention_name>
    <description>Glucophage 1000 mg tablets of Bristol-Myers Squibb</description>
    <arm_group_label>Glucophage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who provided written informed consent.&#xD;
&#xD;
          -  Subjects who were healthy within 18-45 years of age (inclusive) weighing at least 50&#xD;
             kg.&#xD;
&#xD;
          -  Subjects who were within ±10% of ideal body weight in relation to height according to&#xD;
             Life Insurance Corporation of India height-weight chart for non-medical cases.&#xD;
&#xD;
          -  Subjects with normal health as determined by medical history and physical examination&#xD;
             performed within 15 days prior to the commencement of the study.&#xD;
&#xD;
          -  Subjects with normal ECG, X-ray and vital signs.&#xD;
&#xD;
          -  Availability of subject for the entire study period and willingness to adhere to&#xD;
             protocol requirements as evidenced by written informed consent&#xD;
&#xD;
          -  If subject is a female volunteer and&#xD;
&#xD;
               -  is of child bearing potential practicing an acceptable method of birth control&#xD;
                  for the duration of the study as judged by the investigator(s), such as condoms,&#xD;
                  foams, jellies, diaphragm, intrauterine device(IUD), or abstinence.&#xD;
&#xD;
               -  is postmenopausal for at least 1 year.&#xD;
&#xD;
               -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
                  hysterectomy has been performed on the subject)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects incapable of understanding the informed consent.&#xD;
&#xD;
          -  Subjects with BP:≤90/60 or BP≥140/90.&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to Metformin or other&#xD;
             Biguanides.&#xD;
&#xD;
          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal,&#xD;
             endocrine, immunologic, neurologic and haematologic function.&#xD;
&#xD;
          -  Regular smoker who smokes more than ten cigarettes daily and has difficulty in&#xD;
             abstaining from smoking for the duration of each study period.&#xD;
&#xD;
          -  Subjects who has taken over the counter or prescribed medications, including any&#xD;
             enzyme modifying drugs or any systemic medication within the past 30 days prior to&#xD;
             start of clinical period.&#xD;
&#xD;
          -  History of any psychiatric illness, which may impair the ability to provide written,&#xD;
             informed consent.&#xD;
&#xD;
          -  Subjects who have a history of alcohol or substance abuse within the last 5 years.&#xD;
&#xD;
          -  Subjects with clinically significant abnormal values of laboratory parameters.&#xD;
&#xD;
          -  Subjects who have participated in any other clinical investigation using experimental&#xD;
             drug or had bled more than 350 mL in the past 3 months.&#xD;
&#xD;
          -  Subjects who tested positive at screening for HIV, HbsAg or HCV&#xD;
&#xD;
          -  Subjects with positive urine drug screen test for drugs of abuse.&#xD;
&#xD;
          -  Any subject in whom Metformin is contraindicated for medical reasons.&#xD;
&#xD;
          -  Subjects who have used any drugs or substances such as herbal preparations known to be&#xD;
             strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 14&#xD;
             days prior to the first dose.&#xD;
&#xD;
          -  Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
          -  Female volunteers who are currently breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mangesh Kulkarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta Labs Ltd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra pradesh</state>
        <zip>500051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vice President-Generics</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

